Evidence map›Paper›PMID 37415222›Full record

ArticleJournal of translational medicine2023

Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models.

Huiyuan Zhang, Yuchen Du, Lin Qi, Sophie Xiao, Frank K Braun, Mari Kogiso, Yulun Huang, Frank Huang, Aalaa Abdallah, Milagros Suarez and 10 more

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 3 countries.

Huiyuan Zhang *Texas Children's Cancer Center, Houston, TX, USA.
Yuchen Du *Texas Children's Cancer Center, Houston, TX, USA.
Lin QiTexas Children's Cancer Center, Houston, TX, USA.
Sophie XiaoDepartment of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Lurie Children's Hospital of Chicago, Chicago, IL, 60611, USA.
Frank K BraunTexas Children's Cancer Center, Houston, TX, USA.
Mari KogisoTexas Children's Cancer Center, Houston, TX, USA.
Yulun HuangTexas Children's Cancer Center, Houston, TX, USA.
Frank HuangDivision of Experimental Hematology and Cancer Biology, Brain Tumor Center, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, 45229, USA.
Aalaa AbdallahDepartment of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Lurie Children's Hospital of Chicago, Chicago, IL, 60611, USA.
Milagros SuarezDepartment of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Lurie Children's Hospital of Chicago, Chicago, IL, 60611, USA.
Sekar KarthickPediatric Brain Tumor Research Office, Cancer and Stem Cell Biology Program, SingHealth Duke-NUS Academic Medical Center, Humphrey Oei Institute of Cancer Research, National Cancer Center Singapore, Duke-NUS Medical School, 169610, Singapore, Singapore.
Nabil M AhmedTexas Children's Cancer Center, Houston, TX, USA.
Vita S SalsmanTexas Children's Cancer Center, Houston, TX, USA.
Patricia A BaxterTexas Children's Cancer Center, Houston, TX, USA.
Jack M SuTexas Children's Cancer Center, Houston, TX, USA.
Daniel J BratDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Paul L HellenbeckSeneca Therapeutics, Inc, Blue Bell, PA, 19422, USA.
Wan-Yee TeoTexas Children's Cancer Center, Houston, TX, USA.
Akash J PatelDepartment of Neurosurgery, Baylor College of Medicine, Houston, TX, USA. Akash.Patel@bcm.edu.
Xiao-Nan LiTexas Children's Cancer Center, Houston, TX, USA. xiaonan.li@northwestern.edu.ORCID 0000-0002-6719-3789
Baylor College of Medicine · USLurie Children's Hospital · USChildren's Cancer Center · USNorthwestern University · USSingHealth Duke-NUS Academic Medical Centre · SGCincinnati Children's Hospital Medical Center · US

Funding

Matching panels of in vivo and in vitro model system of pediatric brain tumorsU01CA217613 · NCI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI LI, XIAONAN · 2020 to 2024
$2.9M
(PQD-5) Patient derived orthotopic xenograft models for drug response predictionR01CA185402 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LI, XIAONAN · 2014 to 2017
$1.3M
NCI NIH HHS R01 CA185402NCI NIH HHS U01 CA217613
6 · The paper itself

Abstract

backgroundAnimal models representing different molecular subtypes of glioblastoma multiforme (GBM) is desired for developing new therapies. SVV-001 is an oncolytic virus selectively targeting cancer cells. It's capacity of passing through the blood brain barrier makes is an attractive novel approach for GBM. MATERIALS AND

methods23 patient tumor samples were implanted into the brains of NOD/SCID mice (1 × 10

resultsPDOX formation was confirmed in 17/23 (73.9%) GBMs while maintaining key histopathological features and diffuse invasion of the patient tumors. Using differentially expressed genes, we subclassified PDOX models into proneural, classic and mesenchymal groups. Animal survival times were inversely correlated with the implanted tumor cells. SVV-001 was active in vitro by killing primary monolayer culture (4/13 models), 3D neurospheres (7/13 models) and glioma stem cells. In 2/2 models, SVV-001 infected PDOX cells in vivo without harming normal brain cells and significantly prolonged survival times in 2/2 models. When combined with radiation, SVV-001 enhanced DNA damages and further prolonged animal survival times.

conclusionA panel of 17 clinically relevant and molecularly annotated PDOX modes of GBM is developed, and SVV-001 exhibited strong anti-tumor activities in vitro and in vivo.

Indexed as

Brain NeoplasmsGlioblastomaOncolytic VirotherapyOncolytic VirusesAnimalsCell Line, TumorDisease Models, AnimalHumansMiceMice, Inbred NODMice, SCIDXenograft Model Antitumor AssaysGlioblastomaOncolytic virusPatient-derived orthotopic xenograftSVV-001Therapeutic efficacy

Identifiers

PMID37415222
PMCPMC10324131
OpenAlexW4383375912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.